Erratum: Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme (Journal of Crohn's and Colitis (2022) (jjac141) DOI: 10.1093/ecco-jcc/jjac141)

William J. Sandborn, Geert R. D'Haens, Bruce E. Sands, Remo Panaccione, Siew C. Ng, Nervin Lawendy, Nicole Kulisek, Irene Modesto, Xiang Guo, Rajiv Mundayat, Chinyu Su, Ivana Vranic, Julian Panés

Research output: Contribution to journalComment/Letter to the editorAcademic

Abstract

This is an erratum to: William J Sandborn, Geert R D'Haens, Bruce E Sands, Remo Panaccione, Siew C Ng, Nervin Lawendy, Nicole Kulisek, Irene Modesto, Xiang Guo, Rajiv Mundayat, Chinyu Su, Ivana Vranic, Julian Panés, Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme, Journal of Crohn's and Colitis, 2022, jjac141, https://doi.org/10.1093/ecco-jcc/jjac141 In the originally published version of this manuscript, a link for the plain language summary was not included. An infographic plain language summary of this paper is available at: [https://pfizer.figshare.com/articles/journal_contribution/Plain_language_summary_for_the_manuscript_Tofacitinib_for_the_Treatment_of_Ulcerative_Colitis_An_Integrated_Summary_of_up_to_7_8_Years_of_Safety_Data_from_the_Global_Clinical_Programme/21652322] This error has been corrected.
Original languageEnglish
Pages (from-to)462
Number of pages1
JournalJournal of Crohn's and Colitis
Volume17
Issue number3
DOIs
Publication statusPublished - 1 Mar 2023

Cite this